



IFW

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NUMBER YPL-0064 SERIAL NUMBER 10/663,857 FILED 09/15/2003
FIRST INVENTOR: Yeon-su LEE TITLE VARIANT OF HNF-1ALPHA GENE
HAVING NEW SINGLE NUCLEOTIDE POLYMORPHISM AND VARIANT OF
PROTEIN ... EXAMINER Angela Marie Bertagna ART UNIT 1637

1. ☒ Applicant submits herewith a copy of (a) attached form PTO-1449, which lists all patents, publications, applications, or other information submitted for consideration by the Office; (b) a legible copy of each document required by 37 C.F.R. §1.98(b)(2).
2. ☐ Applicant herein apprises the Patent Office of references cited in a parent U.S. application from which this application obtains the benefit of an earlier filing date under 35 U.S.C. §120. The Serial Number of the parent application is U.S. Application _____ filed _____ and entitled _____.
The publications cited therein are listed on attached Form PTO-1449. In accordance with 37 C.F.R. §1.98(d) copies of the listed publications are not required. ☐ Additional parent patent applications are listed on an attached sheet.
3. ☐ In accordance with 37 C.F.R. §1.98(a)(3), Applicant hereby certifies that for each reference not in English (check at least one box below):
☐ A copy of a translation of one or more non-English document, or portion thereof, is provided herewith;
☐ A concise explanation is (check at least one box below):
☐ provided in the accompanying foreign or international search report; ☐ incorporated into the specification; and/or ☐ provided herewith.

37 C.F.R. §1.97(b)(1), (b)(2) – WITHIN 3 MONTHS OF FILING OR ENTRY IN NATIONAL STAGE

4. ☐ Since this Information Disclosure Statement is being filed within three months of the filing date of the subject application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application, no fee or certification under 37 C.F.R. §1.97(e) is required.

37 C.F.R. §1.97(b)(3), (b)(4) – PRIOR TO MAILING OF FIRST OFFICE ACTION OR FIRST ACTION AFTER REQUEST FOR CONTINUED EXAMINATION

5. ☐ Since this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114, no fee or certification under 37 C.F.R. §1.97(e) is required.

37 C.F.R. §1.97(c) – AFTER FIRST ACTION, BEFORE FINAL ACTION OR ALLOWANCE

6. ☒ Since this Information Disclosure Statement is being filed outside of the period provided for in 37 C.F.R. §1.97(b), but before the mailing date of a Final Rejection or Notice of Allowance, this submission is being accompanied by (one of the following boxes must be checked):
 - a. ☐ the fee required under 37 C.F.R. §1.97(c)(2) and specified in 37 C.F.R. §1.17(p).
 - b. ☒ the statement specified in 37 C.F.R. §1.97(e) (Box 8 or 9 must be checked).

37 C.F.R. §1.97(d) – AFTER FINAL REJECTION OR ALLOWANCE


7. ☐ Since this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(c), but on or before payment of the issue fee and is accompanied by both the statement specified in 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p). (Box 8 or 9 must be checked.)
8. ☒ In accordance with 37 C.F.R. §1.97(e)(1), Applicant's attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. ☐ The foreign or international search report(s) is/are enclosed.
9. ☐ In accordance with 37 C.F.R. §1.97(e)(2), Applicant's attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of the information disclosure statement.
10. ☒ In the event the Commissioner of Patents deems that any additional fee is required under 37 C.F.R. §§ 1.16 or 1.17 in connection with this application, Applicant's attorneys authorize that such fee be charged to Deposit Account No. 06-1130.
11. Consideration of this Information Disclosure Statement is respectfully requested.

Name:	Amy Bizon-Copp	Registration Number	53,993
Signature	<i>Amy Bizon-Copp</i>	Date	August 25, 2006

CERTIFICATE OF MAILING OR TRANSMISSION: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or [] facsimile transmitted to the U.S. Patent and Trademark Office to Facsimile No. _____ on the date shown below.

Name	Paula Currie
Signature	<i>Paula Currie</i>
Date	August 25, 2006





INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

YPL-0064

Application Number

10/663,857

Applicant(s)

Yeon-su LEE, et al.

Filing Date

09/15/2003

Group Art Unit

1637

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,187,533 B1	02/13/2001	Bell et al.	435	6	09/09/1997

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

EUROPEAN SEARCH REPORT; APPLICATION NO. EP 06 01 1392; DATE: JULY 14, 2006

All the references cited in the Search Report are listed above

CHOUARD T ET AL: "A distal dimerization domain is essential for DNA-binding by the atypical HNF1 homeodomain"; NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SUREY, GB, vol. 18, no. 19, 1990, pages 5853-5863, XP002190082; ISSN: 0305-1048

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) YPL-0064	Application Number 10/663,857
		Applicant(s) Yeon-su LEE, et al.	
		Filing Date 09/15/2003	Group Art Unit 1637

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	DATABASE EMBL; 5 September 2000; XP002268127; Retrieved from EBI Database accession no. AC079602.15; Nucleotides 139463-139555
	DATABASE EMBL; 19 March 2002; XP002260758; retrieved from EBI Database accession no. AF483515
	"IDENTIFICATION OF NINE NOVEL MUTATIONS IN THE HEPATOCYTE NUCLEAR FACTOR 1 ALPHA GENE ASSOCIATED WITH MATURITY-ONSET DIABETES OF THE YOUNG (MODY3)"; Author: Vaxillaire M. et al. Human Molecular Genetics, Oxford University Press, urrey GB, vol. 6, no. 4, 1 April 1997; pages 583-586, XP002051549; ISSN: 0964-6906
	"MUTATIONS IN THE HEPATOCYTE NUCLEAR FACTOR-1ALPHA GENE IN MATURITY-ONSET DIABETES OF THE YOUNG (MODY3)"; NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 384, no. 6608, 5 December 1996, pages 455-458, XP002051550; ISSN: 0028-0836
	"NOVEL MODY3 MUTATIONS IN THE HEPATOCYTE NUCLEAR FACTOR 1ALPHA GENE. EVIDENCE FOR HYPEREXCITABILITY OF PANCREATIC BETA-CELLS TO INTRAVENOUS SECRETAGOGUES IN A GLUCOSE-TOLERANT CARRIER OF A P447L MUTATION"; Author: HANSEN T ET AL., DIABETES, NY, NY US, vol. 46, no. 4, 1 April 19997, pages 726-730, XP002051548; ISSN: 0012-1797
	"GENETIC VARIATION IN THE HEPATOCYTE NUCLEAR FACTOR-1-ALPHA GENE IN DANISH CAUCASIANS WITH LATE-ONSET NIDDM"; Author: URHAMMER S A ET AL, DIABETOLOGIA, vol. 40, no. 4, 1997, pages 473-475, XP002260756; ISSN: 0012-186X
	"VARIANTS IN THE HEPATOCYTE NUCLEAR FACTOR-1ALPHA AND-4ALPHA GENES IN FINNISH AND CHINESE SUBJECTS WITH LATE-ONSET TYPE 2 DIABETES."; Author: RISSANEN J ET AL; DIABETES CARE. UNITED STATES OCT 2000, vol. 23. no 10, October 2000; pages 1533-1538, XP002260757; ISSN: 0149-5992
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.